Literature DB >> 25788003

Noroviruses as a Cause of Diarrhea in Immunocompromised Pediatric Hematopoietic Stem Cell and Solid Organ Transplant Recipients.

X Ye1, J N Van1, F M Munoz2,3,4, P A Revell2,4,5, C A Kozinetz6, R A Krance2,4, R L Atmar1,3, M K Estes3, H L Koo1,4.   

Abstract

Case reports describe significant norovirus gastroenteritis morbidity in immunocompromised patients. We evaluated norovirus pathogenesis in prospectively enrolled solid organ (SOT) and hematopoietic stem cell transplant (HSCT) patients with diarrhea who presented to Texas Children's Hospital and submitted stool for enteric testing. Noroviruses were detected by real-time reverse transcription polymerase chain reaction. Clinical outcomes of norovirus diarrhea and non-norovirus diarrhea patients, matched by transplanted organ type, were compared. Norovirus infection was identified in 25 (22%) of 116 patients, more frequently than other enteropathogens. Fifty percent of norovirus patients experienced diarrhea lasting ≥14 days, with median duration of 12.5 days (range 1-324 days); 29% developed diarrhea recurrence. Fifty-five percent of norovirus patients were hospitalized for diarrhea, with 27% requiring intensive care unit (ICU) admission. One HSCT recipient developed pneumatosis intestinalis. Three HSCT patients expired ≤6 months of norovirus diarrhea onset. Compared to non-norovirus diarrhea patients, norovirus patients experienced significantly more frequent ICU admission (27% vs. 0%, p = 0.02), greater serum creatinine rise (median 0.3 vs. 0.2 mg/dL, p = 0.01), and more weight loss (median 1.6 vs. 0.6 kg, p < 0.01). Noroviruses are an important cause of diarrhea in pediatric transplant patients and are associated with significant clinical complications. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research / practice; infection and infectious agents; infectious disease; intestinal disease: infectious; pediatrics; viral

Mesh:

Substances:

Year:  2015        PMID: 25788003      PMCID: PMC4780324          DOI: 10.1111/ajt.13227

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  39 in total

1.  Is there a role for oral human immunoglobulin in the treatment for norovirus enteritis in immunocompromised patients?

Authors:  Diana F Florescu; Elizabeth D Hermsen; Joong Y Kwon; Dalal Gumeel; Wendy J Grant; David F Mercer; Andre C Kalil
Journal:  Pediatr Transplant       Date:  2011-08-23

2.  Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation.

Authors:  Stefan Schwartz; Maria Vergoulidou; Eckart Schreier; Christoph Loddenkemper; Mark Reinwald; Martin Schmidt-Hieber; Willy A Flegel; Eckhard Thiel; Thomas Schneider
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

3.  Characterization of norovirus-associated traveler's diarrhea.

Authors:  N Ajami; H Koo; C Darkoh; R L Atmar; P C Okhuysen; Z-D Jiang; J Flores; H L Dupont
Journal:  Clin Infect Dis       Date:  2010-07-15       Impact factor: 9.079

4.  Norwalk virus infection of volunteers: new insights based on improved assays.

Authors:  D Y Graham; X Jiang; T Tanaka; A R Opekun; H P Madore; M K Estes
Journal:  J Infect Dis       Date:  1994-07       Impact factor: 5.226

5.  Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico.

Authors:  Hoonmo L Koo; Nadim J Ajami; Zhi-Dong Jiang; Frederick H Neill; Robert L Atmar; Charles D Ericsson; Pablo C Okhuysen; David N Taylor; A Louis Bourgeois; Robert Steffen; Herbert L DuPont
Journal:  J Clin Microbiol       Date:  2010-03-19       Impact factor: 5.948

6.  Etiology and outcome of diarrhea after marrow transplantation: a prospective study.

Authors:  G J Cox; S M Matsui; R S Lo; M Hinds; R A Bowden; R C Hackman; W G Meyer; M Mori; P I Tarr; L S Oshiro
Journal:  Gastroenterology       Date:  1994-11       Impact factor: 22.682

7.  Two cases of Norwalk virus enteritis following small bowel transplantation treated with oral human serum immunoglobulin.

Authors:  Diana F Florescu; Lisa A Hill; Megan A McCartan; Wendy Grant
Journal:  Pediatr Transplant       Date:  2008-01-24

Review 8.  Norovirus gastroenteritis in immunocompromised patients.

Authors:  Karin Bok; Kim Y Green
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245

9.  Noroviruses: The Most Common Pediatric Viral Enteric Pathogen at a Large University Hospital After Introduction of Rotavirus Vaccination.

Authors:  Hoonmo L Koo; Frederick H Neill; Mary K Estes; Flor M Munoz; Arlin Cameron; Herbert L DuPont; Robert L Atmar
Journal:  J Pediatric Infect Dis Soc       Date:  2012-08-03       Impact factor: 3.164

10.  Diagnosing norovirus-associated infectious intestinal disease using viral load.

Authors:  Gemma Phillips; Ben Lopman; Clarence C Tam; Miren Iturriza-Gomara; David Brown; Jim Gray
Journal:  BMC Infect Dis       Date:  2009-05-14       Impact factor: 3.090

View more
  18 in total

Review 1.  Norovirus Illnesses in Children and Adolescents.

Authors:  Minesh P Shah; Aron J Hall
Journal:  Infect Dis Clin North Am       Date:  2018-03       Impact factor: 5.982

2.  Deep sequencing of phage-displayed peptide libraries reveals sequence motif that detects norovirus.

Authors:  Amy M Hurwitz; Wanzhi Huang; Mary K Estes; Robert L Atmar; Timothy Palzkill
Journal:  Protein Eng Des Sel       Date:  2016-12-28       Impact factor: 1.650

3.  Norovirus Loads in Stool Specimens of Cancer Patients with Norovirus Gastroenteritis.

Authors:  Taojun He; Tracy A McMillen; Yuanyuan Qiu; Liang Hua Chen; Xuedong Lu; Xiao-Li Pang; Mini Kamboj; Yi-Wei Tang
Journal:  J Mol Diagn       Date:  2017-08-12       Impact factor: 5.568

4.  Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication.

Authors:  Wen Dang; Yuebang Yin; Yijin Wang; Wenshi Wang; Junhong Su; Dave Sprengers; Luc J W van der Laan; Krzysztof Felczak; Krzysztof W Pankiewicz; Kyeong-Ok Chang; Marion P G Koopmans; Herold J Metselaar; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

5.  Norovirus in health care and implications for the immunocompromised host.

Authors:  Pearlie P Chong; Robert L Atmar
Journal:  Curr Opin Infect Dis       Date:  2019-08       Impact factor: 4.915

6.  Epidemiology of Norovirus Infection Among Immunocompromised Patients at a Tertiary Care Research Hospital, 2010-2013.

Authors:  Karin Bok; D Rebecca Prevots; Alison M Binder; Gabriel I Parra; Sara Strollo; Gary A Fahle; Allison Behrle-Yardley; Jordan A Johnson; Eric A Levenson; Stanislav V Sosnovtsev; Steven M Holland; Tara N Palmore; Kim Y Green
Journal:  Open Forum Infect Dis       Date:  2016-09-08       Impact factor: 3.835

Review 7.  Chronic norovirus infection and common variable immunodeficiency.

Authors:  J Woodward; E Gkrania-Klotsas; D Kumararatne
Journal:  Clin Exp Immunol       Date:  2016-11-16       Impact factor: 4.330

Review 8.  Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations.

Authors:  Negar Aliabadi; Ben A Lopman; Umesh D Parashar; Aron J Hall
Journal:  Expert Rev Vaccines       Date:  2015-07-29       Impact factor: 5.217

Review 9.  Norovirus in Transplantation.

Authors:  Michael P Angarone; Anna Sheahan; Mini Kamboj
Journal:  Curr Infect Dis Rep       Date:  2016-06       Impact factor: 3.725

10.  Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with Ribavirin by Activation of Cellular Antiviral Response.

Authors:  Lei Xu; Buyun Ma; Wen Dang; Sunrui Chen; Yuebang Yin; Kyeong-Ok Chang; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.